Board of Directors | Management | Investors
______________________________________________________________________________________________
Charles Homcy joined Third Rock Ventures in 2010 as a Venture Partner. Charles co-founded Portola Pharmaceuticals in 2003, and served as President and Chief Executive Officer from that time until April 2010. Prior to that, he was President of Research and Development at Millennium following Millennium's acquisition of COR Therapeutics in 2002. Charles joined COR in 1995 as Executive Vice President of Research and Development, and he served as a Director of the company from 1998 to 2002. He has been a clinical professor of medicine at the University of California, San Francisco Medical School, and attending physician at the San Francisco VA Hospital since 1997. He was previously President of the medical research division of American Cyanamid-Lederle Laboratories, a division of Wyeth. Charles serves as co-chairman of the board of directors of Portola and is a board member of Geron Corporation. Charles received his AB and MD from Johns Hopkins University.
______________________________________________________________________________________________
Neil Exter joined Third Rock Ventures in 2007 and plays an integral role in the overall formation, development and business strategy of its portfolio companies. Additionally, he supports the business development efforts within the portfolio companies. He also assumes active leadership roles in Third Rock's portfolio companies, functioning as interim Chief Operating Officer/Chief Business Officer through the first 12-18 months post-launch. Neil has over 17 years of business development and strategic experience, facilitating the successful development and implementation of operations and collaborations across the spectrum of newly emerging and established biotech companies.
Prior to joining Third Rock Ventures, Neil was CBO of Alantos Pharmaceuticals, leading the sale of the company to Amgen. Previously, Neil served as VP for Millennium Pharmaceuticals, directing in-licensing and M&A. Earlier in his career, Neil held various executive management roles within the high technology industry, including tenures at Hewlett Packard and Wang Laboratories.
Neil holds an MBA as a Baker Scholar from Harvard Business School, a MS from Stanford University and a BS from Cornell University. Neil is a member of the Board of Overseers at Children’s Hospital Boston and a member of the Children’s Hospital Boston Board Research Committee. Additionally, Neil is a member of the Innovation Research Fund at Partners Healthcare and a member of the Advisory Council of the Electrical and Computer Engineering Department at Cornell University.
______________________________________________________________________________________________
Dr. McCarthy has more than 15 years of experience in the biotechnology industry, including business development, venture capital, program management, and research management. Prior to joining CytomX in January 2011, he was a transactional partner at Pappas Ventures, where he helped drive investments in therapeutic, medical device and molecular diagnostic companies, including the formation and financing of Afferent Pharmaceuticals, a new company developing novel pain medications based on programs licensed from Roche. Prior to Pappas Ventures, Dr. McCarthy was vice president of business development at SGX Pharmaceuticals Inc. Under his leadership, SGX entered into a wide range of strategic partnerships with major pharmaceutical companies, including a $515 million oncology alliance with Novartis and a key technology transfer alliance with Lilly. As a member of the management team, Dr. McCarthy also led a strategic re-orientation at SGX that resulted in a successful initial public offering in 2006. Prior to SGX, Dr. McCarthy was associate director of program management at Millennium Pharmaceuticals where he managed therapeutic protein programs anda research team that invented novel genomic techniques for the identification of therapeutic proteins. Dr. McCarthy is the author of 17 peer-reviewed scientific publications and is a named inventor on six issued patents and 23 filed patent applications. He received his D.Phil. in cancer biology from St. John’s College, University of Oxford; his M.B.A. from the Rady School of Management, UC San Diego; and a B.Sc. in biochemistry and pharmacology at King’s College, University of London.
______________________________________________________________________________________________
Fred Gluck is a former managing partner (CEO) of McKinsey & Company, Inc., the international management consulting firm (1967-1995; Managing Director: 1988-1994). Fred retired from McKinsey in 1995, and joined the Bechtel Group, where he served as Vice-Chairman and Director. Fred retired from Bechtel in July 1998, and rejoined McKinsey and Company as a consultant until retiring again in July 2003. Mr. Gluck’s business board memberships include AMGEN (Thousand Oaks, CA) [NASDAQ]. Mr. Gluck also serves as Director of a number of eleemosynary organizations, including the Cottage Health System (Santa Barbara, CA), the Foundation Board of the University of California, Santa Barbara, the Kavli Institute of Theoretical Physics and The New York Presbyterian Hospital (Emeritus).
